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Abstract
 .Vasoconstrictors, such as angiotensin II Ang II , are involved in the regulatory mechanisms of post myocardial
 .  .infarction MI hypertrophy. Arginine vasopressin AVP , may be another vasoconstrictor that influences the mechanisms
that lead to post MI hypertrophy. In these studies we investigated the possible activation of the 42r44 kDa mitogen-activated
 .  .protein kinases MAPKs , also referred as extracellular signal regulated kinases ERKs , in cultured cardiomyocytes.
 .Treatment of rat cardiomyocytes with AVP, Ang II and phorbol 12-myristate 13-acetate PMA increases the activation of
 .  .ERKs. The activity of the 42r44 kDa MAPKs was tested using the phosphorylation of: 1 EGF receptor peptide EGFR-P ;
 .  .  . 183 1852 myelin basic protein MBP immobilized in poly acrylamide gels; and 3 T and Y residues of these proteins. The
 .activity of the MAPKs, induced by AVP or PMA was inhibited by downregulation of protein kinase C PKC , by the
 .tyrosine kinase inhibitor genistein and by MAPK kinase MEK inhibitor, PD98059. In addition, the AVP-induced
stimulation of MAPKs was shown to be mediated through a V receptor. We suggest that AVP activates the 42r44 kDa1
MAPKs through a signal transduction pathway that involves stimulation of AVP-V receptor, tyrosine kinase, PKC and1
MEK. These results suggest that AVP may be involved in ERKs dependent regulatory functions of cardiomyocytes growth.
q 1998 Elsevier Science B.V.
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1. Introduction
 .Mitogen-activated protein kinases MAPKs com-
prise a family of protein serinerthreonine kinases
that are activated by many extracellular stimuli, in-
cluding growth factors and hormones. The extracellu-
 .lar signal regulated kinases ERKs , require phospho-
rylation on both threonine and tyrosine residues in
183 185 w xthe sequence T –E–Y to become active 1,2 .
This dual phosphorylation reaction is carried out by
 . w xspecific enzyme MAPK or ERKs kinase MEK 3 .
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Recently, a selective inhibitor of MEK, PD98059,
w xwas identified 4 and used to evaluate the role of the
w xERKs pathway in insulin action 5 and neuronal
w xdifferentiation 6 . Two forms of ERKs, 42 and
w x44 kDa, were identified in cardiomyocytes 7–10 .
Stimulation of these enzymes was observed during
 .myocyte activation by fetal calf serum FCS , en-
 .  . w xdothelin-1 ET-1 , angiotensin Ang II 7 , acidic
 .fibroblast growth factor aFGF , 12-O-tetrade-
 . w x w xcanoylphorbol-13-acetate TPA 9 and insulin 10 .
In the setting of heart failure, the heart depends on
several compensatory mechanisms for maintenance
of its pumping capacity. One of the major mecha-
nisms is the activation of neurohormonal systems.
The effects include activation of the sympathetic
nervous system with increased plasma cathe-
cholamines, activation of the renin-angiotensin-al-
dosterone system and increased production and re-
 . w xlease of arginine vasopressin AVP 11 . Although
the changes in these systems are compensatory and
are capable of maintaining blood pressure, they may
adverse the effects in patients with congestive heart
failure. The action of AVP is mediated through acti-
vation of specific membrane-bound receptors present
at the surface of the target cells. On the basis of
pharmacological and functional studies the AVP re-
ceptors were classified into V -vascular and V -renal1 2
w xsubtypes 12 . The receptors are coupled to different
intracellular second messengers: V -receptor activa-1
tion is related to inositol phospholipid hydrolysis and
intracellular Ca2q mobilization, whereas V -receptor2
activation leads to an increase of cAMP. Thus, it was
interesting to investigate whether AVP affects the
MAPKs activity in rat myocytes.
In this study, we report that in rat cardiac my-
ocytes activation of MAPKs, in particular ERK1 and
ERK2, are stimulated by AVP. We suggest the partic-
ipation of AVP-V receptor, tyrosine kinase, protein1
 .kinase C PKC , MEK and MAPKs in the AVP-in-
duced signaling pathway.
2. Materials and methods
2.1. Materials
AVP, MBP, phorbol 12-myristate 13-acetate
 .PMA , Ang II and genistein were obtained from
Sigma Chemical Co. The specific MEK inhibitor,
PD98059, was kindly provided by Dr. A.R. Saltiel,
Parke-Davis Pharmaceutical Research Division, Ann
 2 8 a.Arbor. The specific V Phe Orn Vasotocin and V1 2
 a .V D A V P recep to r ag o n is ts an d V1
w  .  .  . bx wdesGly NH d CH Tyr Me AVP and V des-2 2 5 2
 .  . w 2 4 x xGly NH d CH D-Ile ,Ile AVP receptor antag-2 2 5
onists were kindly provided by Dr. M. Manning,
w 32 xM edical C ollege of O hio . g - P A T P
 .3000 Cirmmol was obtained from Amersham Inter-
national. Medium M-199 H was obtained from Bio-
logical Industries, Beit Haemek. A peptide corre-
sponding to ERK2 carboxy-terminal, residues’ 349-
 w x.361 KELIFEETARFQPGY 13 was prepared by
Peninsula Laboratories. This peptide, conjugated to
keyhole limpet hemacyanin, was used for polyclonal
antibody production, in rabbits, according to estab-
lished procedures. Polyclonal antibodies against
ERK1 and the phosphorylated T183 and Y185 residues’
domain of ERKs were obtained from Promega. EGF
 . receptor-peptide EGFR-P ELVEPLTPSGEAPN-
w x.QALLR 14 was prepared by the Weizmann Insti-
 y3 . tute. Stock solutions of PMA 10 M , genistein 2
y2 .  y2 .= 10 M and MEK inhibitor 2 = 10 M were
prepared in dimethylsulfoxide. This solvent was
added, at equal final concentration of 0.25%, to
 y2 .control myocytes. Stock solutions, of AVP 10 M ,
 y2 .V and V receptor agonists and antagonists 10 M1 2
 y3 .and Ang II 10 M , were prepared in 10 mM Na
 .acetate pH 4.0 .
2.2. Myocytes cell culture
Rat myocytes were isolated and cultured in 30 mm
w xculture dishes as described previously 15 .
2.3. Preparation of cell extracts
Myocytes were incubated for 24 h in serum-free
M-199 H medium and stimulated by the agonists
dissolved in stimulation buffer. After 5 min the buffer
was removed and cells were frozen by the addition of
ice-cold lysis buffer and liquid nitrogen lysis buffer
 .contained: 10% glycerol vrv , 25 mM NaCl, 50 mM
NaF, 10 mM Na pyrophosphate, 2 mM Na VO ,2 4
20 mM p-nitrophenyl phosphate and 25 mM Tris-HCl,
.pH 7.4 . After thawing, cells were scraped from the
dishes and sonicated for 5 s at 0-48C in a Branson
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B-30 cell disrupter, at 40% duty cycle. The resulting
homogenate was centrifuged at 17 300 = g for 20 min
at 48C and the supernatant of the cell extracts was
kept at y708C.
2.4. Western blotting for determination of total and
T 183 and Y 185 phosphorylated ERKs
Supernatant were mixed with 1r4 volume of 5x
concentrated sample buffer, followed by heating at
1008C for 5 min 1x sample buffer contained: 3%
 .  .SDS wrv , 0.0015% bromophenol blue wrv , 5%
 .  .2-mercaptoethanol vrv , 11% glycerol vrv and
.70 mM Tris-HCl, pH 6.8 . After separation of ex-
w xtracts by 11% SDS-PAGE 16 , proteins were trans-
ferred to nitrocellulose membrane filters Schleicher
.and Schuell . Membranes were blocked using 3%
nonfat dried milk in phosphate-buffered saline, pH
7.2, and incubated for 16 h with the same buffer
containing ERK2 or ERK1 antibodies. For determina-
tion of ERKs phosphorylation we used the specific
antibody against phosphorylated T183 and Y185
 .residues’ domain of ERKs Promega . Immunoreac-
tive protein bands were visualized using ECL
 .Amersham Western blotting detection system. Agfa
RP2 X-ray films were used in order to detect the
enhanced chemiluminescence of the appropriate
bands.
2.5. MAPKs acti˝ity determination using EGFR-P
Extracts were tested for EGFR-P-kinase activity.
Samples were incubated in kinase buffer for 10 min
at 308C, in a final volume of 30 ml. The kinase buffer
was composed of 20 mM HEPES, pH 7.0, 2 mM
DTT, 10 mM MgCl , 0.1 mgrml bovine serum albu-2
min, 0.1 mM EGTA, 3.3 mgrml protein kinase A
w 32 x  .inhibitor, 100 mM g- P ATP 0.5 mCi and 2 mgrml
EGFR-P. The reaction was terminated by the addition
of 7.5 ml of 5= concentrated sample buffer followed
by heating at 1008C for 5 min. The proteins were
resolved by 15% SDS-PAGE and the phosphorylated
EGFR-P in each sample was identified by auto-
radiography on Agfa RP2 X-ray films. The intensity
of the EGFR-P phosphorylation was obtained by
scanning the films and integrating the specific phos-
phorylated EGFR-P bands, using ImageQuant Per-
sonal Densitometer.
2.6. 42r44 kDa MAPKs acti˝ity determination using
MBP-containing polyacrylamide gels
This determination was performed according to the
w xmethod of Kameshita and Fujisawa 17 with slight
modifications. The proteins in the crude extracts were
w xresolved by 10% SDS-electrophoresis 16 through
 .mini polyacrylamide gels 5.5 = 8.5 cm that contain
 .the substrate 0.5 mg of MBPrml polymerized into
the separation gel. After electrophoresis, the proteins
in the gels were allowed to denature and renature.
Then the gels were immersed for 30 min at 228C in
buffer containing 40 mM HEPES, pH 8.0, 2 mM DTT
and 0.1 mM EGTA. For determination of MBP-kinase
activity the gels were incubated for 1 h at 228C in
7.5 ml of the same buffer, supplemented with 5 mM
w 32 x  .MgCl and 25 mM g- P ATP 25mCirml . The2
location of any MBP kinases in the gels was then
detected by autoradiography. The relative MBP-
kinase activity in the corresponding protein bands
was determined by scanning the films and integrating
the peaks using the ImageQuant and Personal Densit-
ometer Molecular Dynamics system.
3. Results
3.1. Identification of ERKs in myocytes
Due to sequence similarity, but not identity of
w xERK1 and ERK2 in their C-terminus region 13 ,
relatively specific antibodies to ERK1 or ERK2 can
be prepared. In numerous investigations, antibody
cross reactivity was found among the 42 and 44 kDa
variants of MAPK using relatively specific anti ERKs
antibodies. Using western immunobloting procedure,
with specific anti-ERK1 antibody, we demonstrate in
Fig. 1A the existence of both ERK1 and ERK2 in
myocyte cell extracts. The ERK1 antibody cross re-
acts with both the 42 and 44 kDa variants of these
cells expressing similar density in both protein bands.
In addition, we determined these proteins by using
antibody against ERK2 carboxy-terminal peptide re-
.sidues’ 349-361 . The anti-ERK2 antibody recognizes
both ERK1 and ERK2 variants, but cross reacts
 .merely with ERK2 Fig. 1B . Addition of the ERK2
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Fig. 1. Western immunoblots of myocyte extracts. Western im-
 .munoblotting with specific anti-ERK1 panel A or anti-ERK2
 .panel B antibodies that cross react with 42 and 44kDa variants
of MAPK. The effect of ERK2 carboxy-terminal peptide
 .5mgrml on ERK2 antibody binding to myocytes" 42 and
 .44 kDa variants of MAPK panel C . Protein markers in the range
of 18–205kDa were run in order to evaluate the exact M.W. of
the ERKs. The arrows indicate the location of the 42 and 44 kDa
MAPK variants. Panel D demonstrates the densitometric evalua-
 .  .tion of ERK1 lanes 1 and 3 and ERK2 lanes 2 and 4 using
 . antibodies towards ERK1 lanes 1 and 2 or ERK2 lanes 3 and
.4 proteins. In each determination, with both antibodies, the
density of the ERK2 band represents 100%. Shown are graphic
presentations, obtained by scanning films and integrating the
specific ERK1 and 2 bands, using ImageQuant Personal Densito-
meter.
 .carboxy-terminal peptide 5mgrml , abolished the
observed chemiluminescence of both 42 and 44 kDa
MAPK bands that were identified by the anti-ERK2
 .antibody Fig. 1C . These results, emphasize the
specificity of the anti-ERK2 antibody, towards both
42 and 44 kDa variants of MAPK in myocytes. In
Fig. 1D we present the relative densitometric evalua-
tion of ERK1 and ERK2 in myocytes using the
relatively specific antibodies against ERK1 or ERK2.
As indicated in this figure, using anti-ERK1 anti-
body, we obtain in cultured myocytes, similar density
 .111% of ERK1 in comparison to ERK2 band
 .100% . Using antibody that is relatively specific to
 .ERK2, we obtain very low density ;1.5% of
 .ERK1 in comparison to the ERK2 100% . These
observations are in agreement, with relatively high
protein level of ERK2 than ERK1 in rat myocytes.
Fig. 2. The effect of V and V agonists and antagonists on1 2
EGFR-P kinase activity. Myocytes were activated for 5 min by
y7  .  .  .10 M AVP lanes 2–4 . V lane 3 and V lane 4 antagonists1 2
 y6 .10 M were simultaneously added with AVP. Myocytes were
 .  .  y6 .also exposed to V lane 5 and V lane 6 agonists 10 M .1 2
Control myocytes are presented in lane 1. The proteins were
resolved by 15% SDS-PAGE and the phosphorylated EGFR-P in
each sample was identified by autoradiography. Shown are
graphic presentations, obtained by scanning films and integrating
the specific phosphorylated EGFR-P bands, using ImageQuant
Personal Densitometer. Representative of three experiments.
3.2. Characterization of EGFR-P kinase acti˝ation
by AVP in myocytes
In previous studies, it was shown that MAPKs can
669  .phosphorylate thr of the EGFR 14 . As shown in
Fig. 2, AVP stimulates the phosphorylation of EGFR-
 .P lane 2 as compared to unstimulated myocytes
 .lane 1 .The AVP effect is mediated through a V1
receptor, since only the V -receptor specific antago-1
Fig. 3. The effect of AVP, AII and PMA on EGFR-P kinase
y7 y7  .activity. Myocytes were activated by 10 M AVP10 lane 2 ,
 . y7  .M Ang II lane 3 or 5=10 M PMA lane 4 for 5 min. Control
myocytes are presented in lane 1. EGFR-P kinase activity was
determined as described in Fig. 2. Representative of three experi-
ments.
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Fig. 4. The effect of PKC downregulation, genistein and MEK
inhibitor on AVP- and PMA-elevated MAPKs activity. Myocytes
y7  .were activated for 5 min by 10 M AVP panel A, lanes 2–5 or
y7  .by 5 = 10 M PMA panel B, lanes 2–5 . PMA at 2.5 =
10y6 M was added 24 h before stimulation to the cells in lanes 3.
Genistein at 2 = 10y5 M was added to the cells in lanes 4 and
MEK inhibitor at 2.5 = 10y5 M was added to the cells in lanes
5, 15 min before stimulation. Control myocytes are presented in
lane 1. The effect of PKC downregulaton, genistein and MEK
inhibitor administration at the same drug concentration and time
length, was also performed on unstimulated myocytes. EGFR-P
kinase activity was determined as described in Fig. 2. The data
presented are averages of three experiments, each in duplicate
measurements. The bars indicate SE and the stars indicates
statistical differences, versus lane 2, according to student’s t-test
 .))) P -0.001, )) P -0.01, ) P -0.05 .
w x  .nist 18 lane 3 decreased significantly the AVP-
elevated EGFR-P phosphorylation and only the V -1
 .receptor specific agonist lane 5 mimics the AVP-
elevated EGFR-P phosphorylation. Furthermore, the
 .V receptor antagonist lane 4 did not inhibit the2
AVP stimulated EGFR-P phosphorylation and a V2
 .agonist lane 6 did not stimulate this kinase activity
in cultured myocytes. The results in Fig. 3, illustrate
that, AVP-, Ang II- and PMA -activated myocytes
 .treatments 2-4, respectively express stimulation of
EGFR-P kinase activity as compared to control my-
 .ocytes treatment 1 . The agonists ‘concentrations
used for the cells’ EGFR-P kinase activation was at
the maximal stimulatory effect of each agonist data
.not shown . These observations indicate, that the
heterotrimeric G-binding proteins associated recep-
tors of AVP and AII as well as PKC mediate the
increase of MAPKs activity in myocytes.
We compared the effect of PKC down regulation,
w xthe tyrosine kinase inhibitor- genistein 19 and the
 .specific MEK inhibitor PD98059 4–6 on EGFR-P
 .kinase activity stimulated by AVP Fig. 4A or PMA
 .Fig. 4B . The results show that both AVP and PMA
 .treatment 2 Fig. 4 panels A and B, respectively
markedly increase the EGFR-P kinase activity. Both
activities are inhibited by PKC downregulation treat-
.  .ment 3 , by genistein treatment 4 and by the MEK
 .inhibitor treatment 5 . PKC downregulaton, genis-
tein and MEK inhibitor administration at the same
drug concentration and time length to agonist unstim-
 .ulated myocytes, had small 7% at most inhibitory
 .effect on the EGFR-P kinase activity data not shown .
EGFR-P kinase activity is associated with protein
w xkinase activities other than ERKs 20 . The total
inhibitory effect of the specific MEK inhibitor
PD98059 indicates, that the AVP stimulated EGFR-P
kinase activity, measured in rat myocytes, is mostly
related to the stimulation of ERKs.
Fig. 5. In gel MBP kinase activity determination. Myocytes were
y7  . y7  .activated by 10 M AVP lane 2 , 10 M Ang II lane 3 , or 5
y7  .= 10 M PMA lane 4 for 5 min. Control myocytes are
presented in lane 1. The proteins were resolved by 10% SDS–
PAGE and the phosphorylated MBP in each sample was identi-
fied by autoradiography. Protein markers in the range of 18–
205kDa were run in order to evaluate the exact M.W. of the
42r44kDa MAPKs.
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3.3. Acti˝ation of gel immobilized MBP phosphoryla-
tion by AVP, AII and PMA in myocytes
The inhibitory effect of MEK inhibitor on AVP
dependent EGFR-P kinase activity strongly suggests,
but does not confirm that ERK1 and ERK2 are
elevated due to the administration of this vasocon-
strictor to rat myocytes. In comparison to control
 .myocytes lane 1 , it is demonstrated in Fig. 5 that
 .  .  .AVP lane 2 , AII lane 3 and PMA lane 4 signifi-
cantly elevate MBP phosphorylation of 42 or 44 kDa
protein. The data provided in this figure support the
 .observations in this study Figs. 2–4 that AVP sig-
naling increases the activity of ERKs in rat myocytes.
3.4. Acti˝ation of ERKs T 183 and Y 185 phosphoryla-
tion by AVP, AII and PMA in myocytes
In order to conclusively demonstrate that ERKs in
myocytes are activated by AVP, we determined the
T183 and Y185 phosphorylation of these proteins using
specific antibody against their phosphorylated TEY
 .domain Promega . It is illustrated in Fig. 6, that the
TEY domain in both ERK1 and 2, is more phospho-
 .rylated in myocytes treated with AVP lane 2 , AII
 .  .lane 3 and PMA lane 4 as compared to untreated
 .cells lane 1 . But, the level of the ERKs phosphory-
lation is lower after AVP treatment than after AII or
PMA. Interestingly, in agreement with lower expres-
 .sion of ERK1 in comparison to ERK2 Fig. 1 , there
Fig. 6. Determination of T183 and Y185 phosphorylated ERKs.
y7  . y7Myocytes were activated by 10 M AVP lane 2 , 10 M Ang
 . y7  .II lane 3 , or 5 = 10 M PMA lane 4 for 5 min. Control
myocytes are presented in lane 1. The proteins were resolved by
10% SDS-PAGE and the T183 and Y185 phosphorylated ERK1
and 2 in each sample was identified by the Western immuno-
blotting procedure. Protein markers in the range of 18–205kDa
were run in order to evaluate the exact M.W. of the ERKs.
is lower TEY domain phosphorylation of this protein,
in myocytes, after the administration of all three
agonists.
4. Discussion
In this study we have examined the stimulation of
ERKs during AVP, AII and PMA-induced myocyte
activation. Two forms of ERKs, 42 and 44 kDa, were
 .identified in rat myocytes Fig. 1 . Recently, several
studies also identified two forms of 42 and 44 kDa
w xMAPKs in rat cardiomyocytes 7–10 .
The binding of AVP to the V receptor is known to1
induce the rapid hydrolysis of inositol phospholipids,
to generate the intracellular second messengers dia-
cylglycerol, which activates PKC, and phosphatidyli-
nositol 4,5-bisphosphate that mobilizes Ca2q. As
demonstrated in Fig. 2, AVP induces the stimulation
of MAPKs. This stimulation is mediated through a V1
receptor. These results are consistent with previous
studies in which AVP potentiates cardiac L-type Ca2q
currents via V receptor stimulation, in guinea pig1
w xventricular myocytes 21 . Interestingly, AVP induces
changes in peak systolic cell position and Ca2q intra-
cellular concentration via V receptor, in cultured1
w xchick embryo ventricular myocytes 22 .
w xThe agonists - FCS, ET-1, Ang II 7 , aFGF, TPA
w x w x9 and insulin 10 , were shown to activate MAPKs.
Our findings are in agreement with these studies.
Upon myocytes stimulation with AVP, AII or PMA
the EGFR-P kinase activity of MAPK was increased
 .Fig. 3 .
Cardiac myocytes express PKC-alpha, -delta,
-epsilon and -zeta. Exposure to PMA for 24 h down-
regulated PKC-alpha, -delta and -epsilon, but not
w xPKC-zeta 9 . In our study, similar maneuver abol-
ished MAPKs activation on exposure to AVP or on
re-exposure to PMA Fig. 4 panels A and B, respec-
.tively . Therefore, it is concluded that in rat cardiac
myocytes the V receptor-AVP-induced stimulation1
of MAPKs involves activation of PKC-alpha, -delta
or -epsilon. Interestingly, AVP-induced activation of
MAPKs in vascular smooth muscle cells was also
w xmediated through PKC alpha 23 .
We have investigated the role of tyrosine phospho-
rylation in this signaling pathway using the tyrosine
kinase inhibitor–genistein. We find that genistein
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treatment inhibits AVP- and PMA-induced activation
 .of MAPKs activity Fig. 4 . These data indicate that
genistein-sensitive enzyme, probably a tyrosine ki-
nase, is critical for activation of the MAPKs pathway
by AVP and PMA. Since genistein inhibits PMA
activation of MAPK activity, this tyrosine kinase
activity is probably located downstream of PKC.
Interestingly, genistein prevents alpha-adrenergic-in-
duced cardiac cell hypertrophy by inhibiting activa-
w xtion of the Ras-MAPK signaling pathway 24 .
It was demonstrated that carbachol and FCS acti-
vate two variants of MEK, in rat cardiac myocytes
w x7 . In addition, the activity of one major and one
minor MEK variants in myocytes, was stimulated by
w xET-1 or a FGF 9 . In our study, pretreatment of
cardiac myocytes with the specific MEK inhibitor
PD98059, completely blocked the increase in MAPK
 .activity produced by AVP or PMA Fig. 4 . These
data indicate the involvement of MEK in the AVP-in-
duced ERKs pathway. The identity of the MEK
 .  .variant s that participate s in the AVP signaling
pathway remain to be found.
Our study demonstrates the activation of ERK1
and ERK2 by AVP and suggests a possible signaling
pathway for this vasoconstrictor action in cardiomy-
ocytes. The notion, that AVP induces the ERKs
activity in cardiomyocytes, was confirmed by the
observations that this vasoconstrictor activates the
phosphorylation of both gel immobilized MBP by
 .42r44 kDa protein Fig. 5 and ERKs TEY domain
 .Fig. 6 .
This study suggests that release of AVP in the
setting of congestive heart failure, may involve acti-
vation of the myocyte MAPKs signaling pathway.
This signaling pathway includes AVP binding to V1
receptor subtype and subsequent activation of tyro-
sine kinase, PKC, MEK, and MAPK. The involve-
ment of the AVP dependent MAPKs activation, in
the compensatory mechanisms of the failing heart in
vivo, needs further investigation.
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